| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.6 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.6 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.6 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |